(Photo: Shutterstock)
Perrigo Co.'s over-the-counter Opill gained a key recommendation from US regulatory advisers, paving the way for the birth-control pill to get clearance to be sold without a prescription.
Members of two Food and Drug Administration advisory committees voted 17-0 in support of using the progestin-only pill without a prescription, citing studies that support consumers' ability to use the pill properly and touting its public health benefit. The agency isn't required to follow its advisers' recommendations, but often does.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
